DNA

Ginkgo Bioworks Holdings Inc - Ordinary Shares - Class A

The $59B Quiet Shift Reshaping How Patients Access Care The $59B Quiet Shift Reshaping How Patients Access Care PR Newswire VANCOUVER, BC, May 12, 2026 Issued on behalf of VentriPoint Diagnostics...

Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab Ginkgo Bioworks Reports First Quarter 2026 Financial Results...

Ginkgo Bioworks (NYSE:DNA) Trading Up 11.1% - What's Next...

Ginkgo Bioworks Announces Date of First Quarter 2026 Results Presentation Ginkgo Bioworks Announces Date of First Quarter 2026 Results Presentation PR Newswire BOSTON, April 30, 2026 Presentation and Q&A session scheduled for post-market on Thursday, May 7, 2026BOSTON, April 30, 2026 /PRNewswire...

Ginkgo Bioworks (NYSE:DNA) will be releasing its Q1 2026 earnings after the market closes on Tuesday, May 5. (View Earnings Report at...

Ginkgo Bioworks (NYSE:DNA) Stock Price Up 6.9% - Still a Buy...

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Get Free Report) was the target of a significant decline in short interest in March. As of March 31st, there was short interest totaling 6,146,646 shares, a...

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Get Free Report) insider Steven Coen sold 33,171 shares of Ginkgo Bioworks stock in a transaction on Monday, April 13th. The stock was sold at an average price of $6.41, for a total value of $212,626.11. Following the completion of the sale, the insider...

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Get Free Report) insider Steven Coen sold 33,171 shares of the business's stock in a transaction that occurred on Monday, April 13th. The shares were sold...